Steven Cohen's CLDX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 3.23 M shares of Celldex Therapeutics, Inc. (CLDX) worth $102.45 M, representing 0.13% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in CLDX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 1.47 M shares. Largest reduction occurred in Q4 2025, reducing 2.14 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Celldex Therapeutics (CLDX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Celldex Therapeutics (CLDX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1.47 M | Add 83.69% | 3.23 M | $31.72 |
| Q4 2025 | -2.14 M | Reduce 54.84% | 1.76 M | $27.16 |
| Q3 2025 | +1.09 M | Add 38.98% | 3.89 M | $25.87 |
| Q2 2025 | +180,546 | Add 6.89% | 2.8 M | $20.35 |
| Q1 2025 | +105,203 | Add 4.18% | 2.62 M | $18.15 |
| Q4 2024 | +947,264 | Add 60.38% | 2.52 M | $25.27 |
| Q3 2024 | -369,283 | Reduce 19.05% | 1.57 M | $33.99 |
| Q2 2024 | +654,194 | Add 50.96% | 1.94 M | $37.01 |
| Q1 2024 | -1.47 M | Reduce 53.42% | 1.28 M | $41.97 |
| Q4 2023 | +1.41 M | Add 105.31% | 2.76 M | $39.66 |
| Q3 2023 | +157,600 | Add 13.30% | 1.34 M | $27.52 |
| Q2 2023 | +955,297 | Add 416.25% | 1.18 M | $33.93 |
| Q1 2023 | -276,297 | Reduce 54.63% | 229,503 | $35.98 |
| Q4 2022 | +370,800 | Add 274.67% | 505,800 | $44.57 |
| Q3 2022 | +135,000 | New Buy | 135,000 | $28.11 |
| Q2 2021 | -46,100 | Sold Out | 0 | $0.00 |
| Q1 2021 | +46,100 | New Buy | 46,100 | $20.61 |
Steven Cohen's Celldex Therapeutics Investment FAQs
Steven Cohen first purchased Celldex Therapeutics, Inc. (CLDX) in Q1 2021, acquiring 46,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Celldex Therapeutics, Inc. (CLDX) for 17 quarters since Q1 2021.
Steven Cohen's largest addition to Celldex Therapeutics, Inc. (CLDX) was in Q1 2026, adding 3,229,939 shares worth $102.45 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 3,229,939 shares of Celldex Therapeutics, Inc. (CLDX), valued at approximately $102.45 M.
As of the Q1 2026 filing, Celldex Therapeutics, Inc. (CLDX) represents approximately 0.13% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Celldex Therapeutics, Inc. (CLDX) was 3,893,942 shares, as reported at the end of Q3 2025.